Stay updated on GX-188E + Pembrolizumab in HPV+ Cervical Cancer Clinical Trial
Sign up to get notified when there's something new on the GX-188E + Pembrolizumab in HPV+ Cervical Cancer Clinical Trial page.

Latest updates to the GX-188E + Pembrolizumab in HPV+ Cervical Cancer Clinical Trial page
- Check5 days agoChange DetectedUpdates appear to be limited to metadata changes (dates, references); core study content remains unchanged, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check12 days agoNo Change Detected
- Check34 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference4%

- Check41 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0.SummaryDifference0.1%

- Check55 days agoChange DetectedUpdated the page revision from v3.0.1 to v3.0.2. The old revision label was removed and the Back to Top element was dropped; no other core content changes were detected.SummaryDifference0.3%

- Check62 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.3%

- Check70 days agoChange DetectedThe web page has been updated to include specific facility names and locations in South Korea, along with a new reference to a clinical trial involving the GX-188 vaccine and pembrolizumab. The revision number has also been updated.SummaryDifference7%

Stay in the know with updates to GX-188E + Pembrolizumab in HPV+ Cervical Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GX-188E + Pembrolizumab in HPV+ Cervical Cancer Clinical Trial page.